BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32303994)

  • 1. Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany.
    Krüger K; Burmester GR; Wassenberg S; Thomas MH
    Rheumatol Ther; 2020 Jun; 7(2):371-382. PubMed ID: 32303994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
    Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
    BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study.
    D'Angelo S; Tirri E; Giardino AM; Mattucci-Cerinic M; Dagna L; Santo L; Ciccia F; Frediani B; Govoni M; Bobbio Pallavicini F; Grembiale RD; Delle Sedie A; Mulè R; Cantatore FP; Foti R; Gremese E; Conigliaro P; Salaffi F; Viapiana O; Cauli A; Giacomelli R; Arcarese L; Guggino G; Russo R; Puenpatom A; Capocotta D; Nacci F; Anelli MG; Picerno V; Binetti C; Iannone F
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Weinstein CLJ; Meehan AG; Lin J; Briscoe SD; Govoni M
    Clin Rheumatol; 2023 Dec; 42(12):3397-3405. PubMed ID: 37751000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of golimumab in adult patients with rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis and an inadequate response to initial TNFi therapy in Greece: the GO-BEYOND prospective, observational study.
    Athanassiou P; Psaltis D; Georgiadis A; Katsifis G; Theodoridou A; Gazi S; Sidiropoulos P; Tektonidou MG; Bounas A; Kandyli A; Vounotrypidis P; Sakellariou GT; Vassilopoulos D; Huang Z; Petrikkou E; Boumpas D
    Rheumatol Int; 2023 Oct; 43(10):1871-1883. PubMed ID: 37402886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
    Thomas K; Flouri I; Repa A; Fragiadaki K; Sfikakis PP; Koutsianas C; Kaltsonoudis E; Voulgari PV; Drosos AA; Petrikkou E; Sidiropoulos P; Vassilopoulos D
    Clin Exp Rheumatol; 2018; 36(2):254-262. PubMed ID: 29148406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Cantini F; Niccoli L; Nannini C; Cassarà E; Kaloudi O; Giulio Favalli E; Becciolini A; Benucci M; Gobbi FL; Guiducci S; Foti R; Mosca M; Goletti D
    Semin Arthritis Rheum; 2017 Oct; 47(2):183-192. PubMed ID: 28413099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
    Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry.
    Pombo-Suarez M; Sanchez-Piedra C; Garcia-Magallón B; Pérez-Gómez A; Manrique-Arija S; Martín-Doménech R; Colazo M; Campos C; Campos J; Del Pino-Montes J; Arteaga MJ; Cea-Calvo L; Díaz-González F; Gómez-Reino JJ
    Clin Rheumatol; 2021 Oct; 40(10):3979-3988. PubMed ID: 33907904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž; Tomšič M; Praprotnik S;
    Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
    Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
    Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
    Kay J; Rahman MU
    Core Evid; 2010 Jun; 4():159-70. PubMed ID: 20694072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Prospective Study to Evaluate the Impact of Golimumab Therapy on Work Productivity and Activity, and Quality of Life in Patients With Rheumatoid Arthritis, Psoriasis Arthritis and Axial Spondyloarthritis in a Real Life Setting in AUSTRIA. The GO-ACTIVE Study.
    Dejaco C; Mueller T; Zamani O; Kurtz U; Egger S; Resch-Passini J; Totzauer A; Yazdani-Biuki B; Schwingenschloegl T; Peichl P; Kraus A; Naerr GW
    Front Med (Lausanne); 2022; 9():881943. PubMed ID: 35721062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA.
    Iannone F; Favalli EG; Caporali R; D'Angelo S; Cantatore FP; Sarzi-Puttini P; Foti R; Conti F; Carletto A; Gremese E; Cauli A; Ramonda R; Palermo A; Epis O; Priora M; Bergossi F; Frediani B; Salaffi F; Lopalco G; Cacciapaglia F; Marchesoni A; Biggioggiero M; Bugatti S; Balduzzi S; Carriero A; Corrado A; Bongiovanni S; Benenati A; Miranda F; Fracassi E; Perra D; Ferraccioli G; Lapadula G
    Joint Bone Spine; 2021 Jan; 88(1):105062. PubMed ID: 32755721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
    Govoni M; Batalov A; Boumpas DT; D'Angelo S; De Keyser F; Flipo RM; Kellner H; Leroi H; Khalifa A
    Clin Exp Rheumatol; 2024 Mar; 42(3):642-650. PubMed ID: 37976120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Golimumab improves socio economic and health economic parameters in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Krüger K; Burmester GR; Wassenberg S; Thomas MH
    Curr Med Res Opin; 2020 Sep; 36(9):1559-1567. PubMed ID: 32609555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of golimumab in the treatment of arthritis.
    Fleischmann R
    Expert Opin Biol Ther; 2010 Jul; 10(7):1131-43. PubMed ID: 20504106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.